AbstractAbstractPTB Reports,2023,9,2,52-53.DOI:10.5530/PTB.2023.9.8Published:November 2023Type:Drug ReviewAuthors:Juman Alsaab Author(s) affiliations:Juman Alsaab, Pharm D, Ministry of Health, Riyadh, SAUDI ARABIA. Abstract:Registrations: It had been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (S.A.) Trade name (USA); ROLVEDON Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (29.1.2023). General Information: Registered Company: Spectrum Pharmaceuticals. Regulatory Status: R.X. Mechanism of Action: A recombinant human granulocyte growth factor activates signaling pathways that affect cell differentiation, proliferation, migration, and survival by binding to G-CSF receptors on myeloid progenitor cells and neutrophils. Read more... View:PDF (144.44 KB) PDF PDF Images Drug Review: Eflapegrastim Slide ‹ Voluntary/Charitable Pharmacy Practice in Saudi Arabia up Financial Management System in Pharmacy Practice: A New Initiative Project in Saudi Arabia ›